ClinicalTrials.gg
CompletedNCT03293654Updated Mar 23, 2021Results posted

A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

A Phase 1 interventional study of MB02 and US licenced Avastin® in Healthy Volunteers, sponsored by mAbxience Research S.L.. Completed at 2 sites in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the Pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects.

During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

Read the detailed description

The primary PK parameters are Cmax and AUC(0-∞). The PK parameters for bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC[0-∞].and Cmax) and AUC(0-t). The model will include a fixed effect for treatment and body weight as a covariate.

All other PK parameters will not be subject to inferential statistical analysis. Estimates of geometric mean ratios together with the corresponding 90% confidence intervals will be derived for the comparisons of the PK parameters as follows:

  • MB02 versus EU Avastin®
  • MB02 versus US Avastin®
  • EU Avastin® versus US Avastin®

PK similarity will be achieved if the 90% confidence intervals (CIs) for the biosimilar-to-reference ratios of PK endpoints (AUC[0-∞] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®.

All AEs will be listed and summarised using descriptive methodology. All observed or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). All safety data will be listed and summarised as appropriate

Immunogenicity data (overall anti-drug antibody [ADA] incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies before the dose of MB02, EU Avastin®, or US Avastin® (Day 1) and at scheduled postdose assessments will be presented by treatment arm.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

First submitted before mAbxience Research S.L. became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males of any race, between 18 and 55 years of age, inclusive, at Screening.
  2. between 18.5 and 29.9 kg/m2, inclusive, at Screening.
  3. Total body weight between 60 and 95 kg, inclusive, at Screening.
  4. In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
  5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within normal range at Screening and Check in as follows. A single repeat test will be allowed at each timepoint.

    • ≥1.5 × 109 L
    • count ≥100 × 109 L
    • >10 g/dl
    • (ALT) and aspartate aminotransferase (AST) ≤
    • Alkaline phosphatase (ALP) ≤1.5 × ULN
    • Total \<1.5 × ULN (\<51.30 µmol/L in subjects with Gilbert's syndrome)
    • Blood urea nitrogen ≤1.5 × ULN
    • Creatinine \< 132.63 µmol/L
    • Serum albumin: >35 g/L
    • Low density lipoprotein cholesterol ≤ ULN
    • High density lipoprotein cholesterol ≥ lower limit of normal
    • Creatine kinase (CK) \< × 2 ULN
    • (INR) 0.8-1.3
    • Urine dipstick for proteinuria \<2+
  6. Systolic blood pressure ≥90 mmHg and ≤140 mmHg and diastolic blood pressure ≥50 mmHg and ≤90 mmHg at Screening and Check in.
  7. Subjects agree to use as detailed in protocol.
  8. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  3. Any current or recent history of active infections, including localised infections.
  4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit.
  5. Presence of a nonhealing wound or fracture.
  6. Known history of essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions.
  7. Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study.
  8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive alcohol breath test and/or urinary drug test screen at Screening or Check in.
  9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency.
  10. History of clinically signifiant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis.
  11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae.
  12. Alcohol consumption of >24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator.
  14. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study.
  15. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  16. Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee.
  17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  18. Have received a live or attenuated vaccine from 3 months prior to Screening, or have the intention to receive a vaccine during the study.
  19. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing.
  20. Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor.
  21. Use of tobacco- or nicotine-containing products within 5 years prior to Check-in, or positive cotinine test upon Screening or Check-in.
  22. Receipt of blood products within 60 days prior to Check-in.
  23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or from 42 days prior to Screening.
  24. Poor peripheral venous access.
  25. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs.
  26. Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab.
  27. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    MB02 (Bevacizumab Biosimilar)

    Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: MB02

  • Active comparator
    US licenced Avastin®

    Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: US licenced Avastin®

  • Active comparator
    EU approved Avastin®

    Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: EU approved Avastin®

Interventions

  • DrugMB02

    Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

    Also known as: MB02 (Bevacizumab Biosimilar)

  • Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

    Also known as: Bevacizumab (United States)

  • Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.

    Also known as: Bevacizumab (European Union)

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Serum Concentration

    To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  2. AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity

    To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

Secondary outcomes

  1. Tmax: Time of Maximum Observed Serum Concentration

    To evaluate the tmax of MB02, US Avastin® and EU Avastin® .

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  2. AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;

    To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  3. CL: Total Body Drug Clearance After IV Administration

    To evaluate the CL of MB02, US Avastin® and EU Avastin®

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  4. t1/2: Apparent Serum Terminal Elimination Half-life

    To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  5. Immunogenicity

    Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.

    Time frame: Day -1, Day 14, 28, 56, and 78

  6. Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03)

    Compare the incidence of TEAEs reported in each treatment arm.

    Time frame: Day 1 - Day 100

Other outcomes

  1. AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity

    Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  2. AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration

    Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  3. Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration

    Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

    Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

07

Results

Posted Jun 16, 2020

Participant flow

Participant flow — Overall Study
MilestoneMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Started383838
Completed383738
Not completed010
Withdrew: Lost to follow-up010

Outcome measures

PrimaryCmax: Maximum Observed Serum Concentration

To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · (ng/mL)/(mg/mL)
Cmax: Maximum Observed Serum Concentration
(ng/mL)/(mg/mL)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Cmax: Maximum Observed Serum Concentration83000 ± 22.465200 ± 21.974400 ± 25.3
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 1.28 · 90% CI 1.18 to 1.39For the comparison, MB02 represents the numerator and US Avastin represents the denominator.
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.12 · 90% CI 1.03 to 1.22For the comparison, MB02 represents the numerator and EU Avastin represents the denominator.
  • US Licenced Avastin® vs EU Approved Avastin® · Ratio of glsm: 1.14 · 90% CI 1.05 to 1.24Ratio of GLSM, EU is the numerator and US Avastin acts as the denominator
PrimaryAUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity

To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · ng*h/mL
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity
ng*h/mLMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity28200000 ± 16.322900000 ± 17.824500000 ± 15.2
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 1.16 · 90% CI 1.09 to 1.22
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.16 · 90% CI 1.09 to 1.22MB02 represents the numerator and EU Avastin represents the denominator
  • US Licenced Avastin® vs EU Approved Avastin® · Ratio of glsm: 1.07 · 90% CI 1 to 1.13EU Avastin corresponds to the numerator and US Avastin corresponds to the denominator
SecondaryTmax: Time of Maximum Observed Serum Concentration

To evaluate the tmax of MB02, US Avastin® and EU Avastin® .

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Median · h
Tmax: Time of Maximum Observed Serum Concentration
hMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Tmax: Time of Maximum Observed Serum Concentration2.51 (1.62 to 71.98)4.00 (1.62 to 11.98)3.00 (1.57 to 12.00)
SecondaryAUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;

To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · ng*h/mL
AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;
ng*h/mLMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;27400000 ± 15.522300000 ± 16.923700000 ± 14.2
SecondaryCL: Total Body Drug Clearance After IV Administration

To evaluate the CL of MB02, US Avastin® and EU Avastin®

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · l/h
CL: Total Body Drug Clearance After IV Administration
l/hMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
CL: Total Body Drug Clearance After IV Administration0.00814 ± 16.50.0101 ± 17.90.00947 ± 15.4
Secondaryt1/2: Apparent Serum Terminal Elimination Half-life

To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · h
t1/2: Apparent Serum Terminal Elimination Half-life
hMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
t1/2: Apparent Serum Terminal Elimination Half-life451 ± 14.4437 ± 15.5449 ± 19.3
SecondaryImmunogenicity

Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.

Time frame:
Day -1, Day 14, 28, 56, and 78
Reported as:
Count of participants · Participants
Immunogenicity
ParticipantsMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
ADA positive221
nAb positive100
NO seroconversion353637
SecondarySafety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03)

Compare the incidence of TEAEs reported in each treatment arm.

Time frame:
Day 1 - Day 100
Reported as:
Number · participants
Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03)
participantsMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Subjects with TEAEs242825
Subjects with SAEs010
Subjects discontinued due to TEAEs000
Related TEAEs638
TEAEs of mild severity242524
TEAEs of moderate severity4105
TEAEs of severe severity010
Other pre-specifiedAUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity

Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · ng*h/mL
AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity
ng*h/mLMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity1040000 ± 16.3981000 ± 18.11020000 ± 14.5
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.02 · 90% CI 0.962 to 1.07MB02 in numerator and EU Avastin in denominator
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 1.06 · 90% CI 0.996 to 1.13MB02 is numerator and US Avastin is denominator
  • US Licenced Avastin® vs EU Approved Avastin® · Ratio of glsm: 1.04 · 90% CI 0.983 to 1.11EU Avastin in the numerator and US Avastin in the denominator
Other pre-specifiedAUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration

Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · ng*h/mL
AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration
ng*h/mLMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration1010000 ± 15.5955000 ± 17.2991000 ± 13.6
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.02 · 90% CI 0.969 to 1.07MB02: EU Avastin
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 1.06 · 90% CI 0.998 to 1.12MB02: US Avastin
  • US Licenced Avastin® vs EU Approved Avastin® · Ratio of glsm: 1.04 · 90% CI 0.981 to 1.1EU Avastin: US Avastin
Other pre-specifiedCmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration

Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.

Time frame:
Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric mean · (ng/mL)/(mg/mL)
Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration
(ng/mL)/(mg/mL)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration3050 ± 22.42790 ± 22.13110 ± 25.2
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 0.986 · 90% CI 0.903 to 1.08MB02: EU Avastin
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 1.1 · 90% CI 1.01 to 1.19MB02: US Avastin
  • US Licenced Avastin® vs EU Approved Avastin® · Ratio of glsm: 1.12 · 90% CI 1.02 to 1.22EU Avastin: US Avastin

Adverse events

Collected over Study duration (Day 1 - Day 100). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MB02 (Bevacizumab Biosimilar)0/38 (0%)0/38 (0%)24/38 (63.2%)
US Licenced Avastin®0/38 (0%)1/38 (2.6%)28/38 (73.7%)
EU Approved Avastin®0/38 (0%)0/38 (0%)25/38 (65.8%)
Most frequent serious events
Most frequent serious events
EventMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
PurpuraSkin and subcutaneous tissue disorders0/381/380/38
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®
Upper respiratory tract infectionInfections and infestations4/3811/386/38
HeadacheNervous system disorders6/388/388/38
Back painMusculoskeletal and connective tissue disorders1/387/384/38
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/384/385/38
NasophyringitisInfections and infestations2/384/385/38
CoughRespiratory, thoracic and mediastinal disorders4/382/381/38
NauseaGastrointestinal disorders4/380/381/38
Pain in extremityMusculoskeletal and connective tissue disorders0/384/383/38
Nasal congestionRespiratory, thoracic and mediastinal disorders0/380/383/38
DiarrhoeaGastrointestinal disorders3/381/380/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
<=18 years0000
Between 18 and 65 years383838114
>=65 years0000
Age, Continuous
Age, Continuous(years)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
Mean36 ± 10.835 ± 9.138 ± 9.937 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
Female0000
Male383838114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
American Indian or Alaska Native0000
Asian0527
Native Hawaiian or Other Pacific Islander0000
Black or African American3249
White35303095
More than one race0123
Unknown or Not Reported0000
Weight
Weight(kg)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
Mean76.9 ± 9.3877.9 ± 8.1177.8 ± 8.2977.6 ± 8.55
BMI
BMI(kg/m^2)MB02 (Bevacizumab Biosimilar)US Licenced Avastin®EU Approved Avastin®Total
Mean24.3 ± 2.6624.3 ± 2.6125.0 ± 2.0724.5 ± 2.46
08

Study locations

2 sites
  • PAREXEL International - Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
  • Covance Clinical Research Unit Limited
    Leeds, LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2019, 17 months.

Results were first posted in Jun 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2017
First posted
Sep 26, 2017
StartActual
Dec 7, 2017
Primary completionActual
May 29, 2019
CompletionActual
May 29, 2019
Results first posted
Jun 16, 2020
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03293654
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Dec 7, 2017
Primary completion
May 29, 2019
Completion
May 29, 2019
Results posted
Jun 16, 2020
Last update
Mar 23, 2021

Study contacts

Sunu Valasseri, MBBS, MSc
principal investigator · Covance
Muna Albayaty, MBChB,FFPM,MSc
principal investigator · Parexel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MB02

Start the discussion